ArticleKidney international reports2026
Renal Response Status and Long-Term Kidney Outcomes in Childhood-Onset Lupus Nephritis.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Paediatric lupus nephritis: defining remission and the evolving therapeutic landscape.Pediatric nephrology (Berlin, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The aim of this study was to evaluate the relationship between modified primary efficacy renal response (PERR, mPERR) and modified complete renal response (CRR, mCRR) at 24 months postbiopsy and long-term kidney outcomes in childhood-onset lupus nephritis (LN, cLN). Methods: We conducted a cohort study of biopsy-proven cLN diagnosed at the age of <18 years between 2001 and 2023, with prospective data collected from 2021 to 2025. We examined the relationship between modified versions of PERR (mPERR) and CRR (mCRR) at 24 months postbiopsy and survival free from advanced chronic kidney disease (CKD), including kidney failure (CKD 4-5D/T). Results: One hundred seven Chinese children (93 female; median age at diagnosis: 13.7, interquartile range [IQR]: 11.0-16.6 years) were analyzed. Ninety-seven (91%) had proliferative LN. The median observation period was 12.0 (IQR: 6.4-17.8) years. At 24 months postbiopsy, 93 (87%) and 81 (76%) subjects were mPERR and mCRR responders, respectively. Kaplan-Meier analysis showed mPERR responders at 24 months had superior CKD 4-5D/T-free survival (responders: 100%, 98.8%, and 97.2%; nonresponders 92.9%, 78.6%, and 78.6% at 1, 5, and 10 years following 24 months postbiopsy; log-rank Conclusion: mPERR at 24 months predicts long-term kidney survival in cLN. Achieving mPERR and mCRR shows significant benefits on lower risk of renal relapse.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.